An enzyme immunoassay procedure for cancer antigen 125 evaluated.
The performance of a new enzyme immunoassay (EIA) procedure (Abbott Labs.) for cancer antigen 125 (CA 125) met or exceeded the manufacturer's claims for all analytical variables examined. Overall correlation with results obtained with a radioimmunoassay (RIA) were good. However, near the decision thresholds typically chosen to define a positive result for ovarian carcinoma, EIA results were 10 to 20 arbitrary units/mL less than the RIA results. At specific decision thresholds, therefore, the sensitivities and specificities of the EIA and RIA procedure differed. Adjusting the decision thresholds gave a similar optimum efficiency for each procedure: EIA, 82.9% (decision threshold, 35 units/mL); RIA, 83.4% (decision threshold, 54 units/mL). Receiver-operating characteristic curves showed that the two procedures' ability to distinguish patients with active ovarian carcinoma from those with disease in remission was the same.
Ryder
K W
KW
Department of Pathology, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis 46202.
Oei
T O
TO
Hull
M T
MT
Sample
M M
MM
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D010051:Ovarian Neoplasms / Q000032:analysis; D011863:Radioimmunoassay
D015295:Antigens, Tumor-Associated, Carbohydrate